US FDA approves antibacterial Besivance for pink eye
29 May 2009
Asher Mullard
Please Login to read the full article.
29 May 2009
Asher Mullard
The US FDA has approved Bausch & Lomb's Besivance (besifloxacin ophthalmic suspension 0.6%; formerly referred to by the trade name Optura) as a treatment for bacterial conjunctivitis in patients aged one year and older.
Besivance is an antibacterial eye drop that functions by...
Please Login to read the full article.
RELATED CONTENT
NEWS
- InSite to raise $22M to advance PhIII pipeline including combo product for lid margin disease
- Merck increases focus on ophthalmology market with $430M acquisition of Inspire
- EU fidaxomicin approval another feather in Optimer's 2011 cap
- Indian gatifloxacin ban excludes ophthalmic products
ANALYSIS
Other Informa Analysis
FEATURES
Other Informa Features
EVENTS
Today
London
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
JOB OF THE WEEK
Promote your vacancy here
